Below you'll find a list of all posts that have been tagged as “life sciences”
The life sciences organizations that consistently make better decisions aren’t necessarily the ones with the most data, they’re the ones that have built competitive intelligence into the fabric of how they plan and act. Drawing on primary research, expert interviews, and Sedulo Group’s Annual Life Sciences CI Survey, this post outlines five practical recommendations for elevating CI from a reporting function to a true driver of strategic impact.
A breakdown of the most important Pharma CI Europe 2026 insights, from evolving competitive dynamics to the strategic shifts redefining pharma launch and commercialization.
A leading pharmaceutical company partnered with Sedulo Group to build a continuous competitive intelligence program tracking innovators, biosimilars, and emerging therapies across the rapidly evolving insulin market. The engagement combined ongoing competitor monitoring, primary intelligence, and quarterly landscape reporting to support stronger portfolio decisions and confident preparation for new market entrants.
Pharmaceutical workshops turn competitive intelligence into actionable strategy. By aligning cross-functional teams, they help organizations interpret market dynamics and prepare for critical moments across the drug lifecycle.
Pharmaceutical competitive intelligence transforms raw competitor, regulatory, and market data into forward-looking strategic insight that helps life sciences companies anticipate competitor moves, shape evidence and launch planning, and make decisions that drive differentiated performance across the drug development lifecycle.
Competitive intelligence has become a strategic necessity in life sciences as pipelines grow more complex and competition accelerates. This article explores how CI teams are evolving to deliver earlier, more actionable insights that support high-stakes decision-making.
A global pharmaceutical company partnered with Sedulo to gain continuous visibility into competitive dynamics across four therapeutic areas. The result was faster BD scouting, clearer portfolio prioritization, and more confident strategic decisions.
Artificial intelligence is increasingly shaping life sciences competitive intelligence, but most organizations are still early in practical adoption. Sedulo Group’s research shows that while many CI teams see efficiency gains from AI, few have fully embedded it into standardized, decision-ready workflows.
The 2025 Life Sciences CI Survey Report reveals how CI functions are evolving, highlighting structural trends, the strategic value organizations place on early threat detection, and the growing yet measured role of AI in shaping competitive insight and decision-making across the industry.
A biopharma leader partnered with Sedulo on a multi-year competitive intelligence program to connect early clinical signals with commercial strategy. The engagement delivered continuous insights across 10 rare disease areas, enabling faster decisions, earlier warnings, and confident portfolio planning.
